Faculty
Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit, Ochsner Clinic
Foundation
James R Gavin III, MD, PhD
Clinical Professor of Medicine at Emory University School of Medicine
Medical Writer
Diep Koly, MD
|
Release date: December 1, 2005
Available for credit through: December 1, 2008
|
Program Description
The incidence and prevalence of diabetes and cardiovascular diseases (CVD) have reached epidemic proportions in the United States and continue to rise at an alarming rate. Cardiovascular diseases are currently the number 1 killer in America followed closely by diabetes, which ranks as the 6th most common cause of death. Peroxisome proliferator-activated receptors (PPARs), ligand activated transcription factors, which have a role in many physiological processes, are promising targets for the treatment of these conditions. This panel discussion is designed to provide primary care providers, endocrinologists, and cardiologists, who are at the forefront in preventing and treating diabetes and CVD, with comprehensive and up-to-date information on the role of PPARs in the treatment of insulin resistance, diabetes and CVD. An expert panel will discuss the interrelationship and impact of diabetes, metabolic syndrome and CVD; current treatment strategies and unmet needs; and safety and efficacy data on PPAR activators; rationale for the clinical application of dual α-γ PPAR activators. |
Target Audience
This activity is intended for primary care physicians, endocrinologists, and cardiologists. |
Program Objectives
Upon completion of this activity, participants should be able to:
- Understand the interrelationship and impact of diabetes, metabolic syndrome, and CVD
- Identify unmet needs in the prevention and treatment of diabetes, metabolic syndrome, and CVD
- Understand the rationale for using PPAR activators in the treatment of insulin-resistant diabetes and CVD
- Discuss the safety and efficacy results of clinical studies involving PPAR agonists and their significance for practice
|
Disclaimer
©2005 Scinexa, LLC. All rights reserved. None of the contents may be reproduced in any form without prior written permission from Scinexa.
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Bristol-Myers Squibb Company, any other manufacturer of pharmaceuticals, ArcMesa Educators, or Scinexa, LLC.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option. |
Copyright © 2005 Scinexa,
LLC / CME Discovery / ArcMesa Educators, LLC. All rights reserved.
|
|